Radioactive Iodide (131I) Treatment of 124I PET/CT Detected Breast Cancers

Inclusion Criteria:

   - Patients with measurable locally advanced or metastatic breast cancer who completed
   124I PET/CT imaging study.

   - Patients who are 18 years of age or older.

   - Patients must have a life expectancy of at least 3 months.

   - I 124 dosimetry completed with thyroid dose to 500 cGy or less and tumor dose of 2500
   cGy or more.

   - I131 therapeutic dose calculated from dosimetry. Dose must be in a range of 25 to 150
   mCi.

   - Patients with Eastern Cooperative Oncology Group (ECOG) Performance Status 0-3 will be
   eligible.

   - Use of concurrent systemic therapy (hormonal or cytotoxic) if associated with stable
   disease for at least three months prior to treatment.

   - Women with locally advanced breast cancer and simultaneous metastases, even if surgery
   to eradicate local disease has taken place.

   - Thyroid stimulating hormone (TSH) must be < 0.4 uIU/mL.

   - White blood cell count >= 1,500 and platelet count >= 40,000

   - Women receiving thyroid hormone supplements and methimazole.

   - Ability to understand and the willingness to sign a written informed consent document.

   - Premenopausal women must use contraception while receiving this treatment and during
   follow-up period of 42 days.

Exclusion Criteria:

   - Stage 0-II breast cancer.

   - Pregnant or nursing women.

   - Not able to sign informed consent.

   - Untreated psychiatric disorder.

   - Women who have not had I124 PET/CT scan and dosimetry calculations.

   - Radioiodide uptake in non-target organs or bone marrow does not exceed 25 cGy by
   pre-treatment dosimetry.

   - Received chemotherapy less than 4 weeks before.

   - History of thyroid cancer.